CU24718B1 - Nuevas formulaciones de comprimido de fosfomicina - Google Patents

Nuevas formulaciones de comprimido de fosfomicina

Info

Publication number
CU24718B1
CU24718B1 CU2022000009A CU20220009A CU24718B1 CU 24718 B1 CU24718 B1 CU 24718B1 CU 2022000009 A CU2022000009 A CU 2022000009A CU 20220009 A CU20220009 A CU 20220009A CU 24718 B1 CU24718 B1 CU 24718B1
Authority
CU
Cuba
Prior art keywords
fosphomycin
new
tablet formulations
relates
tablet
Prior art date
Application number
CU2022000009A
Other languages
English (en)
Other versions
CU20220009A7 (es
Inventor
Ollé Ramon Francesch
Ortega Marta Prior
Original Assignee
Labiana Health S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labiana Health S L filed Critical Labiana Health S L
Publication of CU20220009A7 publication Critical patent/CU20220009A7/es
Publication of CU24718B1 publication Critical patent/CU24718B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>La presente invención se refiere a formulaciones de comprimido de fosfomicina trometamol y a métodos de fabricación de las mismas. Más específicamente, se refiere a una composición farmacéutica oral en forma de comprimido que comprende:</p> <p>a. fosfomicina trometamol;</p> <p>b. hidrogenofosfato de calcio anhidro; y</p> <p>c. celulosa microcristalina anhidra.</p> <p> </p>
CU2022000009A 2021-02-10 2022-02-04 Nuevas formulaciones de comprimido de fosfomicina CU24718B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21382104 2021-02-10

Publications (2)

Publication Number Publication Date
CU20220009A7 CU20220009A7 (es) 2023-09-07
CU24718B1 true CU24718B1 (es) 2024-08-15

Family

ID=74732835

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000009A CU24718B1 (es) 2021-02-10 2022-02-04 Nuevas formulaciones de comprimido de fosfomicina

Country Status (11)

Country Link
US (1) US11833250B2 (es)
EP (1) EP4043006B1 (es)
AR (1) AR124833A1 (es)
BR (1) BR102022002475A2 (es)
CA (1) CA3147662A1 (es)
CO (1) CO2022001244A1 (es)
CU (1) CU24718B1 (es)
ES (1) ES2970581T3 (es)
MX (1) MX2022001746A (es)
PE (1) PE20221446A1 (es)
TW (1) TW202245740A (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118078757A (zh) * 2024-01-25 2024-05-28 南京海纳制药有限公司 一种含磷霉素氨丁三醇的药物组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021725A1 (it) 2002-08-01 2002-10-31 Zambon Spa Composizioni farmaceutiche ad attivita' antibiotica.
ES2244333B1 (es) 2004-05-18 2006-08-01 Simbec Iberica, Sl Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos.
TW201129386A (en) 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
ES2385158B1 (es) 2010-12-24 2013-05-28 Arafarma Group, S.A. Composición farmacéutica de fosfomicina
US8604078B2 (en) 2011-04-06 2013-12-10 Carlos Picornell Darder Fosfomycin pharmaceutical composition

Also Published As

Publication number Publication date
EP4043006C0 (en) 2023-12-06
ES2970581T3 (es) 2024-05-29
AR124833A1 (es) 2023-05-10
TW202245740A (zh) 2022-12-01
US11833250B2 (en) 2023-12-05
EP4043006B1 (en) 2023-12-06
EP4043006A1 (en) 2022-08-17
US20220387329A1 (en) 2022-12-08
PE20221446A1 (es) 2022-09-21
CU20220009A7 (es) 2023-09-07
BR102022002475A2 (pt) 2022-08-23
CA3147662A1 (en) 2022-08-10
CO2022001244A1 (es) 2023-02-16
MX2022001746A (es) 2022-08-11

Similar Documents

Publication Publication Date Title
CY1123549T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
MX2023002117A (es) Forma amorfa de un inhibidor de malt1 y formulaciones de este.
MA34653B1 (fr) Sels du dimethylamide de l&#39;acide 7-cyclopentyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylique et leurs procedes de fabrication
CO6351689A2 (es) Formulaciones farmaceuticas que contienen ligandos de receptores de dopamina
BRPI0908052A2 (pt) Composições farmacêuticas de entacapone, levodopa e carbidopa com biodisponibilidade melhorada
EA201890193A1 (ru) Композиция для ухода за полостью рта
CY1114190T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CU24718B1 (es) Nuevas formulaciones de comprimido de fosfomicina
AR067140A2 (es) Nuevo procedimiento de tratamiento de frutas o legumbres mediante el ion fosforoso y las composiciones correspondientes
DK1746980T3 (da) Farmaceutisk doseringsform omfattende pellets såvel som deres fremstillingsfremgangsmåde
MX2022000762A (es) Formulaciones orales de edaravone y metodo de fabricacion de las mismas.
BR122016006880B8 (pt) forma de dosagem contendo pantoprazol como ingrediente ativo
UA91485C2 (ru) лечебно-профилактическАЯ смесЬ для ухода за полостью рта
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
ATE314076T1 (de) Fosinopril-formulierung
CL2008002828A1 (es) Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno.
ECSP13013043A (es) Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma
JOP20220211A1 (ar) تركيبات صيدلانية من أملاح إستر كولين حمض ليبويك وطرق للمعالجة باستخدامها
MX2023012468A (es) Compuestos como inhibidores de pd1/pd-l1 y metodos de los mismos.
PE20250842A1 (es) Formulaciones orales de acetato de abiraterona y metodo de fabricacion de las mismas
MX2025012194A (es) Composicion farmaceutica oral, proceso para la produccion de granulos o una composicion farmaceutica oral, granulo farmaceutico oral, uso de la composicion farmaceutica y metodo para tratar afecciones inflamatorias, dolores y/o moderar el uso de opioides perioperatorios
CO2022000503A2 (es) Composiciones sólidas orales de liberación inmediata de múltiples unidades, métodos y usos de las mismas
ECSP055997A (es) Vacuna de vibrio cholerae inactivada en tabletas
EA201190243A1 (ru) Стабильная фармацевтическая композиция флударабина фосфата
EA201201372A1 (ru) Способ получения фармацевтической композиции и продукт способа